Physician profile
Opal Thakar
NPI 1659792802
$5,683.81
in general payments reported to CMS, 2019-2025
31 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $525 · 2021: $558 · 2022: $343 · 2023: $1,045 · 2024: $1,375 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,786.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,367.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $756.07 | 2021-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $711.31 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $385.68 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $344.16 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $305.85 | 2019-2025 | Steglatro, Belsomra, Steglujan |
| Lilly USA, LLC | $276.22 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $247.25 | 2019-2025 | |
| Amarin Pharma, INC. | $208.31 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $172.18 | 2024 | Nuedexta |
| Amgen INC. | $167.93 | 2025 | Krystexxa, Otezla, Repatha |
| Abbott Laboratories | $120.64 | 2020-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $106.84 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.74 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $57.60 | 2022-2025 | Gvoke Hypopen |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $56.32 | 2020-2021 | |
| Dynavax Technologies Corporation | $51.48 | 2024 | Heplisav-B |
| Axsome Therapeutics, INC. | $47.90 | 2023 | Sunosi |
| Lundbeck LLC | $33.09 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $30.01 | 2021 | |
| Sanofi Pasteur INC. | $24.28 | 2019-2020 | |
| Astellas Pharma US INC | $23.47 | 2025 | Veozah |
| Mannkind Corporation | $18.28 | 2024 | |
| Sumitomo Pharma America, INC. | $18.28 | 2025 | Gemtesa |
| Corcept Therapeutics | $17.33 | 2025 | Korlym |
| Ibsa Pharma INC. | $15.61 | 2024 | Licart, Tirosint |
| Idorsia Pharmaceuticals US INC | $14.72 | 2023 | Quviviq |
| Ironwood Pharmaceuticals, INC | $12.77 | 2020 | |
| Allergan, INC. | $11.73 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Opal Thakar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.